Clearside Biomedical(CLSD) - 2023 Q4 - Annual Results

• Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - Dr. Lasezkay continued, "Our proprietary SCS Microinjector® enables reliable, simple, in-office, nonsurgical drug delivery into the suprachoroidal space targeted directly to the site of disease in the back of the eye. This trusted delivery method, combined with axitinib's differentiated mechanism of action and high potency, offers the potential fo ...